Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasis against a cohort on nonbiologic systemic th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Dermatol
Autors principals: Yiu, Z.Z.N., Ashcroft, D.M., Evans, I., McElhone, K., Lunt, M., Smith, C.H., Walton, S., Murphy, R., Reynolds, N.J., Ormerod, A.D., Griffiths, C.E.M., Warren, R.B.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379582/
https://ncbi.nlm.nih.gov/pubmed/30070708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.17036
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars